Envision Pharma Group’s Post

Last month, I enjoyed highlighting how technological advancements drive significant changes in medical affairs strategy and execution with some of the industry's greatest minds. If you missed the event, don't worry! We're happy to get you a recording, but don't miss my biggest takeaways on its benefits for the front line of patient perspectives, HCPs: - As they increasingly require direct interactions with medical teams, using technology like AI to gather data and insights from diverse sources enables greater personalization and more impactful interactions. - By leveraging large language models (LLMs) and multi-modal models, we capitalize on AI's dynamic analysis, shortening the development continuum and personalizing data to HCP-specific needs, improving accessibility and decision-making, thus elevating patient care. When AI is working seamlessly in the background, its benefits and impacts are priceless. Still, getting to that point requires significant investments in the right technology, people, and processes. 

Explore new and innovative tools and techniques being used to convert research data and biological insights into clean, actionable data for integration, visualization, and analysis. The Digitization of Clinical Development and Clinical Trials symposium at #BioITExpo looks at how #digitalhealth technologies, #dataanalytics, #machinelearning, and #artificialintelligence can accelerate the translation of scientific discoveries from the bench to medical care. This symposium is one of many tracks, workshops, and symposia you can join. Please take a moment to review the full program here:  https://bit.ly/47NsqTK A few highlights from the Symposium: 👉 Artificial Intelligence in Clinical Development for Precision Medicine Yilin Xu, Principal Data Scientist, Data Science, AbbVie, Inc. 👉 Establish Reverse Translation Sotirios Perdikeas 👉 CO-PRESENTATION: People, Process, Technology: Digital Transformation of the Clinical Data Flow Julia Fox and Julie Gorenstein 👉 Unlocking Data for Analytics for Enterprise Clinical Development Mike Farnum

Excited to attend Bio-IT World this week, showcasing Unison's groundbreaking technology and engaging in discussions on #AI in #DrugDiscovery, #Bioinformatics platforms, #MultiModalData, and more. @ Unison, we've developed technology that enables rapid, seamless federation of disparate phenotype and molecular datasets, and that accelerates data harmonisation by up to 50%, ensuring interoperability while cutting costs and saving time. Example use cases: ⚡ Federating and interoperating across internal molecular and biobank data. ⚡ Federating and harmonising hospital record system data. ⚡ Federating and harmonising historical clinical trial data. We provide the infrastructure for our clients to maximise the value of their data through their bioinformatics research, while laying the foundation for developing the AI models of the future. PM me here to connect at Bio-IT World and to discuss how Unison can revolutionise your data management and analytics! #BioITWorld #DataFederation #DataHarmonisation #Interoperability.

As global concerns for environmental sustainability grow, more biotech firms are adopting AI to promote eco-friendly practices. AI transforms traditional drug development, speeding up candidate identification, predicting efficacy, and refining chemical structures from vast datasets. At QuantHealth, we are taking this approach to reduce physical experiments, cut energy use, minimize waste in trials, and optimize manufacturing by streamlining processes with machine learning. To learn more about how QuantHealth is engineering clinical trials with AI visit https://quanthealth.ai/

Accelerating Drug Discovery: IDM Insight's AI powered Solution to Research Roadblocks Powered by AI: IDM Insight Seamlessly integrates advanced algorithms and machine learning to accelerate drug discovery. Prioritize compounds and targets based on therapeutic potential and utilize our Generative AI tool for novel molecule design. Access over 2 million compounds, from preclinical to approved drugs, in one comprehensive platform. Our databases stand out with unmatched comprehensiveness, integrating data from diverse sources for confident decision-making. Dive into physico-chemical properties, bioactivities, and more, aiding rational drug design. Explore interconnected databases for a holistic view of biological pathways and disease mechanisms, supporting drug readdressing and repurposing campaigns. Read the full article to discover how IDM Insight is shaping the future of medicinal chemistry. #DrugDiscovery #MedicinalChemistry #AIIntegration #ResearchInnovation #IDMInsight #ScienceAdvancements

While 2023 was marked by real success stories in the life sciences and healthcare space, the industry faced unprecedented challenges. Our Life Sciences team examine the trends driving a more favourable outlook for 2024, including: 💊 Why biopharma transactions will stand out as a bright spot for M&A ✨ The potential of AI and data-driven offerings revolutionising healthcare 🌍 Antitrust continues to play an expanding global role, with the sector increasingly under the spotlight Read our new blog on what to expect in 2024 for the life sciences industry: https://okt.to/d5G1I9 #LifeSciences #BioPharma #Antitrust #AI

This week’s #WhatsUpWednesday feature is The Alliance for Artificial Intelligence in Healthcare (AAIH) member and Foley Hoag LLP Partner Colin Zick who will be joining a panel discussion at the Bioprocessing Venture, Innovation and Partnering Conference in Boston, MA on “AI & Technology: Navigating Innovation, Technological Advancements, and Evolving Regulations” today, August 21, 2024 at 1:25 pm EST. This panel will explore AI innovation, regulatory frameworks, and technological advancements in bioprocessing and drug development. Key discussions will include AI's role in data management, process optimization, quality control, and operational efficiency, as well as regulatory challenges and opportunities. Additionally, the panel will also examine the implications of the Loper Bright decision, which may allow courts to overturn FDA regulations, and the US-EU collaborative efforts to evaluate AI technologies. Event URL: https://lnkd.in/ghBruhKn Event Agenda: https://lnkd.in/e-9CPYJK #AAIH #AAIHmember #aitechnology #aiinnovation

Big pharma is buzzing about AI's potential to revolutionize drug discovery. Is it all hype, or are we on the cusp of a medical breakthrough? This interview dives into the current state of AI in pharma research, exploring the challenges and the promise it holds for the future of medicine. https://lnkd.in/g-NsxPp3

Last month, Michael Chen, our CEO, participated in a thought-provoking panel at HLTH Europe titled "Thrills, Pills, & VC Bills: What Will it Take to Unleash Innovation in the World of Drug Development?". The panel explored the integration of advanced technologies like artificial intelligence, high-throughput screening, and computational modeling in drug development. These innovations are revolutionizing the identification of potential drug candidates and the prediction of their efficacy and safety profiles, bringing rapid innovation closer to reality.  🚀 Key takeaways from the panel include: ● The transformative role of AI in accelerating drug discovery and optimizing clinical trials. ● The impact of high-throughput screening in reducing initial testing times. ● The potential of computational models to streamline preclinical and clinical phases. The importance of technologies like eProtein Discovery for accelerating protein production, a critical step in drug development. Michael, along with Karen Madden (Merck Life Science), Geraldine O'Keeffe (EQT Partners), and Ignacio H. Medrano (SAVANA), emphasized the importance of collaboration and the need for increased investment to support innovative projects.  #HLTHEurope #proteinacess

Big pharma is buzzing about AI's potential to revolutionize drug discovery. Is it all hype, or are we on the cusp of a medical breakthrough? This interview dives into the current state of AI in pharma research, exploring the challenges and the promise it holds for the future of medicine. https://lnkd.in/ecT7UJi9